KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Non Operating Income (2016 - 2025)

Travere Therapeutics' Other Non Operating Income history spans 13 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 2004.82% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.6 million, up 448.92%, while the annual FY2025 figure was $11.6 million, 448.95% up from the prior year.
  • Other Non Operating Income reached $11.1 million in Q4 2025 per TVTX's latest filing, up from $487000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $11.1 million in Q4 2025 to a low of -$7.6 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is $527333.3, with a median of $227000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 1638.81% in 2024, then surged 2004.82% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$1.1 million in 2021, then soared by 883.87% to $8.6 million in 2022, then plummeted by 83.93% to $1.4 million in 2023, then tumbled by 142.29% to -$581000.0 in 2024, then soared by 2004.82% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Non Operating Income are $11.1 million (Q4 2025), $487000.0 (Q3 2025), and -$526000.0 (Q2 2025).